LARGO, Fla.--(BUSINESS WIRE)--CONMED Corporation (NYSE: CNMD) today announced the departure of Todd Garner from his role as Chief Financial Officer effective March 15, 2026. To ensure a smooth and orderly transition, Mr. Garner will remain with the Company in an advisory capacity through November 2, 2026. CONMED has initiated a comprehensive search process, supported by a leading executive search firm, to identify its next Chief Financial Officer. "On behalf of our Board and leadership team, I. ...

Key Takeaways CONMED sees growth in BioBrace, AirSeal and Buffalo Filter as adoption strengthens across key platforms.Robotics expansion and rising ASC penetration support multi-year growth and increased AirSeal usage.Tariffs and slower supply-chain recovery weigh on gross margin, with dV5 integration delaying AirSeal demand.CONMED Corporation (CNMD) is well-positioned for growth on the back of rising adoption of its high-margin, differentiated platforms like AirSeal, Buffalo Filter and BioBrace. The compan ...

The last three or so months have been rough ones for CONMED ( CNMD ) ("Conmed") as management continues restructuring efforts aimed at resolving significant supply challenges and repositioning the company over timeAnalyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than ...

Core Insights - Core & Main, Inc. (CNM) is a leading distributor in the water, wastewater, storm drainage, and fire protection products sector in the United States, serving municipalities, private water companies, and professional contractors [1] - CNM reported earnings per share of $0.89, exceeding the estimated $0.73, and revenue of approximately $2.06 billion, slightly above the estimated $2.05 billion [6] Financial Performance - The company's price-to-earnings (P/E) ratio is around 22.57, indicating that investors are willing to pay $22.57 for every $1 of earnings [2] - CNM's price-to-sales ratio stands at about 1.26, showing that investors are paying $1.26 for every dollar of sales [3] - The enterprise value to sales ratio is around 1.57, reflecting the company's total valuation compared to its sales [3] - The enterprise value to operating cash flow ratio is approximately 19.71, indicating the relationship between the company's valuation and its cash flow from operations [4] - The earnings yield is about 4.43%, providing insight into the return on investment for shareholders [4] Financial Health - The company's debt-to-equity ratio is approximately 1.23, highlighting its financial leverage [5] - The current ratio of about 2.26 suggests that CNM has more than twice the current assets compared to its current liabilities, indicating good short-term financial health [5]

Core Insights - CONMED (CNMD) has announced its intention to exit its gastroenterology product lines, including an early conclusion of its distribution agreement with W. L. Gore & Associates, Inc. for the VIABIL biliary stent, as part of a broader portfolio reshaping effort [1][4][5] - The company aims to sharpen its focus on core growth areas such as minimally invasive and orthopedic soft tissue surgery, which is expected to enhance resource allocation and improve long-term margin profiles [1][3][4] Financial Impact - Following the announcement, CNMD's shares fell over 9%, with a year-to-date decline of 41.5%, contrasting with the industry's 11% growth and the S&P 500's 19.2% increase [2] - The gastroenterology product lines are projected to generate $90–$95 million in revenues in 2025, with gross margins around 45%. However, the exit is expected to result in an earnings per share (EPS) dilution of 45–55 cents in 2026 [6] - Once the exit is fully completed, CNMD anticipates an improvement in its consolidated gross margin profile by approximately 80 basis points [6] Strategic Focus - The decision to exit the gastroenterology portfolio is part of a broader strategy to optimize the company's offerings, allowing for a more concentrated investment in areas with higher innovation potential and competitive positioning [4][5] - Management believes that this strategic shift will enhance operating efficiency and support more durable, margin-accretive growth over time [3][7] - By shedding a lower-margin segment, CNMD aims to build a more scalable and resilient operating model [7]

A month has gone by since the last earnings report for Conmed (CNMD) . Shares have added about 0.1% in that time frame, underperforming the S&P 500.Will the recent positive trend continue leading up to its next earnings release, or is Conmed due for a pullback? Well, first let's take a quick look at the latest earnings report in order to get a better handle on the recent drivers for CONMED Corporation before we dive into how investors and analysts have reacted as of late.CONMED Q3 Earnings and Revenues Beat ...

Core Insights - CONMED Corporation (CNMD) is positioned for growth due to the rising adoption of its high-margin platforms like AirSeal, Buffalo Filter, and BioBrace, alongside increasing robotic procedure volumes and the expansion of Ambulatory Surgery Centers (ASCs) [1][4][5] - The company faces challenges from tariff impacts on gross margins and the launch of Intuitive Surgical's da Vinci 5, which delays AirSeal demand [2][11][13] - CONMED has a market capitalization of $1.38 billion and projects a 6.3% earnings growth for 2026, with a history of surpassing earnings estimates [3] Growth Drivers - The adoption of high-margin platforms is strong, with BioBrace expanding to over 70 procedures, AirSeal gaining traction for its clinical benefits, and Buffalo Filter benefiting from smoke-evacuation mandates [4][7] - The expansion of robotic surgery and ASC penetration is expected to provide structural long-term growth opportunities [5][8] - Supply chain improvements are unlocking lost revenue and margin, with significant progress reported in orthopedic supply chain recovery [9] Strategic Focus - A comprehensive portfolio review is ongoing, focusing on high-return segments such as minimally invasive surgery, robotic platforms, and orthopedic soft-tissue repair [10] - Management aims to concentrate resources on these areas to improve margins and enhance shareholder value [10] Challenges - Tariffs are compressing gross margins, with an expected impact of 150 basis points in the fourth quarter [11] - The supply chain recovery is taking longer than anticipated, which may delay revenue recovery and affect market share [12] - The integration of the dV5 system limits the immediate opportunity for AirSeal adoption [13] Financial Outlook - There is a rising estimate revision trend for 2025, with the Zacks Consensus Estimate for earnings moving up to $4.49 per share [14]

Core Viewpoint - The article highlights CONMED (CNMD) as a strong value stock opportunity, supported by various financial metrics indicating it is undervalued compared to its industry peers [4][8]. Financial Metrics - CNMD has a Zacks Rank of 2 (Buy) and a Value grade of A, indicating strong potential for value investors [4][3]. - The stock's P/E ratio is 10.69, significantly lower than the industry average of 18.29, suggesting it is undervalued [4]. - CNMD's PEG ratio stands at 1.62, compared to the industry average of 1.85, indicating favorable earnings growth expectations [5]. - The P/S ratio for CNMD is 1.02, lower than the industry average of 1.38, reinforcing its undervalued status [6]. - The P/CF ratio is 8.23, well below the industry average of 18.79, highlighting strong cash flow relative to its peers [7].

Core Viewpoint - Investors in the Medical - Dental Supplies sector should consider Conmed (CNMD) and Merit Medical (MMSI) as potential value opportunities, with CNMD appearing to be the superior option based on valuation metrics [1]. Valuation Metrics - Both CNMD and MMSI currently hold a Zacks Rank of 2 (Buy), indicating positive earnings estimate revisions for both companies [3]. - CNMD has a forward P/E ratio of 9.52, while MMSI has a forward P/E of 23.65, suggesting that CNMD is more attractively priced [5]. - The PEG ratio for CNMD is 1.41, compared to MMSI's PEG ratio of 2.46, indicating that CNMD offers better value relative to its expected earnings growth [5]. - CNMD's P/B ratio is 1.31, while MMSI's P/B ratio is 3.38, further supporting the conclusion that CNMD is undervalued compared to MMSI [6]. - Based on these valuation metrics, CNMD holds a Value grade of A, whereas MMSI has a Value grade of C, reinforcing the view that CNMD is the superior value option [6].

Core Insights - Zacks Premium offers various tools for investors to enhance their stock market strategies and confidence [1] - The Zacks Style Scores are designed to help investors identify stocks with the potential to outperform the market in the short term [2] Zacks Style Scores Overview - The Style Scores consist of four categories: Value Score, Growth Score, Momentum Score, and VGM Score, each targeting different investment strategies [3][4][5][6] - Value Score focuses on identifying undervalued stocks using financial ratios [3] - Growth Score emphasizes a company's financial health and future growth potential [4] - Momentum Score identifies trends in stock prices and earnings estimates to optimize entry points [5] - VGM Score combines all three styles to highlight stocks with the best overall characteristics [6] Zacks Rank and Its Importance - The Zacks Rank is a proprietary model that uses earnings estimate revisions to guide investment decisions [7] - Stocks rated 1 (Strong Buy) have historically outperformed the S&P 500, with an average annual return of +23.93% since 1988 [7] - Investors are encouraged to select stocks with a Zacks Rank of 1 or 2 and Style Scores of A or B for optimal success [9] Company Spotlight: Conmed Corporation - Conmed Corporation is a global medical technology company specializing in surgical devices for orthopedics and general surgery [11] - The company operates in two segments: Orthopedics and General Surgery, offering innovative products like BioBrace and advanced energy devices [11] - Conmed holds a Zacks Rank of 2 (Buy) and a VGM Score of A, indicating strong growth potential [12] - The company is projected to achieve year-over-year earnings growth of 7.7% for the current fiscal year, with recent earnings estimates revised upward [12][13]